We’ll soon be able to assess the effect of the Gilenya launch on US sales of Copaxone, but I expect that any loss of share by Copaxone will be negligible. For now, Gilenya is apt to have a material adverse effect on BIIB, but not on Teva or MNTA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.